Data as of Q4 2025 (Dec 31, 2025)

LB PHARMACEUTICALS INC

(LBRX)

Financial Statements · SEC EDGAR XBRL

Net Income
-$25.2M
+60.1%
EPS
$-3.13
+98.2%
FCF
-$35.3M
+34.5%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Non-Operating Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
$16.7M
$51.2M
$30.4M
$64.8M
$5.2M
$1.7M
-$25.2M
-$63.1M
$1K
$1K
-$25.2M
-$63.1M
$-3.13
$-176.15
$-3.13
$-176.15
8.0M
358K